Learn more about the latest TB vaccine research here: TAG’s TB Vaccines Pipeline Report Learn more about the Global TB CAB here: 10-Year TB CAB Anniversary Evaluation Report and Podcast Learn more about TAG’s work on pre-approval access…
This policy brief describes the crucial role NIH plays in supporting research on new products to prevent, diagnose, and cure TB. This research is especially important at a time when new forms of drug resistance are emerging globally, and rates of TB are rising in the U.S. With continued and increased funding, NIH can protect Americans from the growing threat of TB at home and abroad.
The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB.
To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:
TAG is pleased to share the latest edition of our Tuberculosis Vaccines Pipeline Report, written by TB project co-director Mike Frick. The report provides the latest information on 17 vaccine candidates under clinical development and summarizes ongoing, planned, and recently completed clinical trials in two comprehensive tables.
Treatment Action Group (TAG) opposes in the strongest possible terms the termination of National Institutes of Health (NIH) research awards and contracts to South Africa, feared following reporting by Science.
TAG was proud to sign on to this 2/3/25 letter created by HIV Health Care Access Working Group (HHCAWG) of the Federal AIDS Policy Partnership (FAPP).
TAG submitted this this input for the Office of the High Commissioner on Human Rights (OHCHR), in response to its request for "Inputs for the comprehensive report, incl. new developments, in ensuring access to medicines, vaccines and other health products."
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.
Your donation will bring progress, healing, and hope — turning the promise of innovative research into a brighter, healthier future for all.
